{"id":169,"date":"2019-01-29T15:47:58","date_gmt":"2019-01-29T06:47:58","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=169"},"modified":"2019-05-15T11:29:55","modified_gmt":"2019-05-15T02:29:55","slug":"publications2014","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/publications2014\/","title":{"rendered":"2014"},"content":{"rendered":"

\u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09<\/strong><\/h4>\n
    \n
  1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u306e\u4eca\u5f8c\u306e\u5c55\u671b\uff0c\u300cSurgery Frontier\uff5e\u7279\u96c6\uff1a\u764c\u3068\u5fae\u5c0f\u74b0\u5883\u300d\uff0c21(2)\uff0c53-57\uff0c2014<\/li>\n
  2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u3068\u65b0\u305f\u306a\u6cbb\u7642\u6226\u7565\u3078\u306e\u5c55\u671b,\u300c\u75c5\u7406\u3068\u81e8\u5e8a\uff5e\u7279\u96c6\uff1a\u304c\u3093\u3068\u9593\u8cea\u300d,32(1), 45-50, 2014<\/li>\n<\/ol>\n

    \u82f1\u8a9e\u8ad6\u6587<\/strong><\/h4>\n
      \n
    1. Kibria G., Hatakeyama H.,Akiyama K.,\u00a0<\/u><\/em>Hida K<\/u>. and Harashima H.\uff1aComparative Study of the Sensitivities of Cancer Cells to Doxorubicin, and Relationships between the Effect of the Drug-Efflux Pump P-gp\uff0cBiol. Pharm. Bull.<\/em><\/strong>37(12), 1926\u20131935, 2014<\/li>\n
    2. Ohmura-Kakutani H\u00a7<\/strong>., Akiyama K.\u00a7<\/strong>, Maishi N., Ohga N., Hida Y., Kawamoto T., Iida J., Shindoh M., Y.\u00a0*Hida K.<\/u>\uff1aIdentification of Tumor Endothelial Cells with High Aldehyde Dehydrogenase Activity and a Highly Angiogenic Phenotype,PLoS ONE<\/em><\/strong>, in press.<\/li>\n
    3. Akhter A., Hayashi Y., Sakurai Y., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aLigand density at the surface of a nanoparticle and different uptake mechanism: Two important factors for successful siRNA delivery to liver endothelial cells,\u00a0Int J Pharm<\/em><\/strong>\uff0c475 (1-2):227-237, 2014<\/li>\n
    4. Ara MN., Matsuda T., Hyodo M, Sakurai Y, Ohga N.,\u00a0Hida K.<\/u>\uff1aConstruction of an aptamer modified liposomal system targeted to tumor endothelial cells,\u00a0Bio Pharm Bull,\u00a0<\/em><\/strong>37(11):1742-9, 2014<\/li>\n
    5. Alam MT.\u00a7<\/strong>\uff0c Nagao-Kitamoto H.\u00a7<\/strong>, Ohga N., Akiyama K., Maishi N., \u00a0Kawamoto T., Shinohara N., Taketomi A., Shindoh M., Hida Y. and\u00a0*Hida K.<\/u>\uff1aSuprabasin as a novel tumor endothelial cell marker,\u00a0Cancer Sci<\/em><\/strong>,105(12), 1533\u20131540, 2014<\/li>\n
    6. Ara MN., Matsuda T., Hyodo M, Sakurai .Y, Hatakeyama H., Ohga N.,\u00a0Hida K.<\/u>, Harashima H. \uff1aAn aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells\uff0cBiomaterials<\/em><\/strong>, 35(25), 7110-7120, 2014<\/li>\n
    7. Ara MN., Hyodo M., Ohga N., Akiyama K.,\u00a0Hida K<\/u>., Hida Y., Shinohara N., Harashima H.\uff1aIdentification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand,\u00a0Cancer Med<\/em><\/strong>, 3(4), 825-834, 2014<\/li>\n
    8. Otsubo T., Hida Y., Ohga N., Sato H., Kai T., Matsuki Y., Takasu H., Akiyama K., Maishi N., Kawamoto T., Shinohara N., Nonomura K.,\u00a0*Hida K<\/u>.\uff1aIdentification of Novel Targets for Antiangiogenic Therapy by Comparing the Gene Expressions of Tumor and Normal Endothelial Cells,\u00a0Cancer Sci<\/i><\/b>, 105(5), 560-567, 2014<\/li>\n
    9. Habiba U., Kitamura T. Yanagawa-Matsuda A.,\u00a0Hida K.<\/u>, Higashino F., Ohiro Y., Totsuka Y. and Shindoh M.\uff1aCytoplasmic expression of HuR may be a valuable diagnostic tool for determining the potential for malignant transformation of oral verrucous borderline lesions,\u00a0Oncol Rep<\/i><\/b>, 31(4), 1547-1554, 2014<\/li>\n
    10. Sakurai Y., Hatakeyama H., Sato Y., Hyodo M., Akita H.,Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aRNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system,\u00a0J Control Release<\/em><\/strong>, 173(10), 110-118, 2014<\/li>\n<\/ol>\n

      \u62db\u5f85\u8b1b\u6f14<\/strong><\/h4>\n
        \n
      1. Maishi N.,\u00a0Hida K<\/u>.\uff1aThe 17th HU-SNU JOINT SYMPOSIUM \u201cCharacterization of tumor endothelial cells for development of new anti-angiogenic therapy\u201d, 2014.11.28\uff08Sapporo, Japan\uff09<\/li>\n
      2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5317\u6d77\u9053\u5927\u5b66\u907a\u4f1d\u5b50\u75c5\u5236\u5fa1\u7814\u7a76\u6240\u30fb\u91d1\u6ca2\u5927\u5b66\u304c\u3093\u9032\u5c55\u5236\u5fa1\u7814\u7a76\u6240\u30b8\u30e7\u30a4\u30f3\u30c8\u30b7\u30f3\u30dd\u30b8\u30a6\u30e02014\uff0c\u201c\u816b\u760d\u8840\u7ba1\u306e\u7570\u5e38\u6027\u7372\u5f97\u30e1\u30ab\u30cb\u30ba\u30e0\u306b\u3064\u3044\u3066\u201d\uff0c2014.10.27\uff08\u672d\u5e4c\uff09<\/li>\n
      3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c1\u56de\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\uff0c\u201cTumor-derived exosome miRNA induce abnormality in tumor endothelial cells\u201d\uff0c2014.8.28\uff08\u5e83\u5cf6\uff09<\/li>\n
      4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u91d1\u6ca2\u5973\u6027\u304c\u3093\u7814\u7a76\u8005\u30d5\u30a9\u30fc\u30e9\u30e0\uff0c\u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u3068\u65b0\u305f\u306a\u6cbb\u7642\u6cd5\u958b\u767a\u201d2014.7.30\uff08\u91d1\u6ca2\uff09<\/li>\n
      5. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c41\u56de\u65e5\u672c\u6bd2\u6027\u5b66\u4f1a\u5b66\u8853\u5e74\u4f1a\u30df\u30cb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u8010\u6027\u306e\u65b0\u305f\u306a\u30e1\u30ab\u30cb\u30ba\u30e0\uff1a\u8fb2\u85ac\u304b\u3089\u6297\u304c\u3093\u5264\u3001\u6297\u30a6\u30a3\u30eb\u30b9\u85ac\u307e\u3067\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u201d\uff0c2014.7.4\uff08\u795e\u6238\uff09<\/li>\n
      6. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u516c\u958b\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3059\u308b\u30ca\u30ce\u533b\u7642\u306e\u5b9f\u7528\u5316\u306b\u5411\u3051\u3066\u62e0\u70b9\u5f62\u6210\uff5e\u304c\u3093\u3092\u59cb\u3081\u3068\u3059\u308b\u56fd\u6c11\u75c5\u3092\u8840\u7ba1\u304b\u3089\u6cbb\u7642\u3059\u308b\uff5e\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u591a\u69d8\u6027\u89e3\u660e\u3068\u500b\u5225\u5316\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u6cd5\u306e\u958b\u767a\u201d2014.6.27\uff08\u672d\u5e4c\uff09<\/li>\n
      7. \u9593\u77f3\u5948\u6e56<\/u>\uff1a\u516c\u958b\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3059\u308b\u30ca\u30ce\u533b\u7642\u306e\u5b9f\u7528\u5316\u306b\u5411\u3051\u3066\u62e0\u70b9\u5f62\u6210\uff5e\u304c\u3093\u3092\u59cb\u3081\u3068\u3059\u308b\u56fd\u6c11\u75c5\u3092\u8840\u7ba1\u304b\u3089\u6cbb\u7642\u3059\u308b\uff5e\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u591a\u69d8\u6027\u89e3\u660e\u3068\u500b\u5225\u5316\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u6cd5\u306e\u958b\u767a\u201d, 6.27\uff08\u672d\u5e4c\uff09<\/li>\n
      8. Maishi N.,\u00a0Hida K<\/u>.\uff1a17th International Congress on Oral Pathology and Medicine, \u201cCharacterization of tumor endothelial cells for development of new anticancer drugs\u201d, 2014.5.26 (Istanbul, Turkey)<\/li>\n
      9. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c68\u56deNPO\u6cd5\u4eba\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u300c\u304c\u3093\u3092\u9593\u8cea\u304b\u3089\u8003\u3048\u308b\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u3068\u65b0\u305f\u306a\u6cbb\u7642\u6cd5\u958b\u767a\u201d\uff0c2014.5.8\uff08\u6771\u4eac\uff09<\/li>\n
      10. Hida K.<\/u>\uff1a\u201dTumor endothelial cells as key players in tumor microenvironment.\u201d International Symposium on Vascular Biology and Medicine, 2014.4.18\uff08Sendai, Japan\uff09<\/li>\n
      11. Hida K.<\/u>\uff1a\u201dHeterogeneity of tumor endothelium\u201d, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n<\/ol>\n

        \u56fd\u969b\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
          \n
        1. Maishi N.,\u00a0Hida K<\/u>.\uff1a\u201cCharacterization of tumor endothelial cells for development of new anti-angiogenic therapy\u201d, The 17th HU-SNU JOINT SYMPOSIUM, 2014.11.28\uff08Sapporo, Japan\uff09<\/li>\n
        2. Maishi N.,\u00a0Hida K<\/u>.\uff1a17th International Congress on Oral Pathology and Medicine, \u201cCharacterization of tumor endothelial cells for development of new anticancer drugs\u201d, 2014.5.26 (Istanbul, Turkey)<\/li>\n
        3. Hida K.<\/u>\uff1a\u201dTumor endothelial cells as key players in tumor microenvironment.\u201d International Symposium on Vascular Biology and Medicine, 2014.4.18\uff08Sendai, Japan\uff09<\/li>\n
        4. Hida K.<\/u>\uff1a\u201dHeterogeneity of tumor endothelium\u201d, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        5. Akiyama K., Ohga N., Hida Y., Maishi N., Alam Mohammad Towfik, Kawamoto T., Omura H., Yamada Y., Torii C., Shindoh M., Ohba Y.,\u00a0Hida K.,<\/u>\u00a0P-gp inhibitor enhances antiangiogenic activity in metronomic chemotherapy, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        6. Maishi N., Ohba Y., Ohga N., Akiyama K., Hamada J., Yamamoto Y., Kawamoto T., Shindoh M., Hida Y.,\u00a0Hida K.<\/u>: Tumor endothelial cells promote metastasis, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        7. Alam Mohammad Towfik, Nagao H., Ohga N., Akiyama K., Maishi N., Kawamoto T., Shinohara N., Taketomi A., Shindoh M., Hida Y.,\u00a0Hida K.<\/u>: SBSN is a novel Tumor Endothelial Cell marker, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        8. Akino T., Nakayama H., Nonomura K.,\u00a0Hida K.<\/u>, Michael Klagsbrun : Netrin-1 promotes medulloblastoma cell invasiveness, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        9. Yamada K., Maishi N. Ohga N., Akiyama K., Kawamoto T., Alam Mohammad Towfik, Shindoh M. Takahashi N., Kamiyama T., Hida Y., Taketomi A.,\u00a0Hida K.<\/u>\u00a0: CXCL12\/CXCR7 axis is important for tumor endothelial cell angiogenic property, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n
        10. Torii C., Ohga N., Akiyama K., Maishi N., Hojo T., Ohiro Y., Ono M., Totsuka Y., Kitagawa Y., Tei K., Hida Y., Shindoh M., Sato Y.,\u00a0Hida K.<\/u>: Vasohibin-1 as a novel prognostic factor in oral squamous cell carcinoma, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japa<\/li>\n
        11. Hojo T., Maishi N., Akiyama K., Ohga N., Kondoh M., Shindoh M., Fujisawa T., Hida Y.,\u00a0Hida K.<\/u>\u00a0: Proangiogenic phenotype of Tumor Endothelial Cells induced by ROS accumulation, The 18th International Vascular Biology Meeting, 2014. 4.14-17, Kyoto, Japan<\/li>\n<\/ol>\n

          \u56fd\u5185\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
            \n
          1. \u9593\u77f3\u5948\u6e56\uff1aTumor endothelial cells instigate metastasis of indolent tumors, IGM\u30ea\u30b5\u30fc\u30c1\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff08\u7b2c6\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff09\uff0c2014.12.25\uff08\u672d\u5e4c\uff09<\/li>\n
          2. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c1\u56de\u516d\u7532\u533b\u5b66\u7814\u7a76\u4f1a\uff0c2014.11.7\uff08\u795e\u6238\uff09<\/li>\n
          3. \u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u816b\u760d\u7d30\u80de\u306e\u76f8\u4e92\u4f5c\u7528\uff0c\u7b2c56\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a\uff0c2014.9.26\uff08\u798f\u5ca1\uff09<\/li>\n
          4. \u79cb\u91ce\u6587\u81e3\uff0c\u4e2d\u5c71\u5bdb\u5c1a\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff0cKlagsbrun M.\uff1aNetrin-1\u306fmedulloblastoma\u306e\u6d78\u6f64\uff0c\u5897\u6b96\u3092\u4fc3\u9032\u3059\u308b\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
          5. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u9ad8\u6a4b\u5178\u5f66\uff0c\u795e\u5c71\u4fca\u54c9\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCXCR7\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u306e\u53ef\u80fd\u6027\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
          6. \u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u4e5f\u5b50\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5185\u4f4e\u9178\u7d20\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u306e\u95a2\u9023\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
          7. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
          8. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38\uff0c\u6238\u585a\u9756\u5247\uff0c\u677e\u91ce\u5409\u5f18\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u4f50\u85e4\u9756\u53f2\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50\u3068\u3057\u3066\u306eVasohibin-1\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
          9. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aROS\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u53ca\u307c\u3059\u5f71\u97ff\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
          10. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u5c71\u672c\u548c\u5e78, \u5ddd\u672c\u6cf0\u8f14,\u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c79\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u30fb\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2014.6.19-20\uff08\u672d\u5e4c\uff09<\/li>\n
          11. \u5b89\u6c38\u8ce2\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0cAlam Mohammad Towfik\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u95a2\u9023\u56e0\u5b50Biglycan \u306e\u767a\u73fe\u3068\u6a5f\u80fd\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.26\uff08\u5e83\u5cf6\uff09<\/li>\n
          12. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.24\uff08\u5e83\u5cf6\uff09<\/li>\n
          13. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b,\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38,\u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50\u3068\u3057\u3066\u306eVasohibin-1\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.24\uff08\u5e83\u5cf6\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            \u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09 \u6a0b\u7530\u4eac\u5b50\uff1a\u816b\u760d\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u306e\u4eca\u5f8c\u306e\u5c55\u671b\uff0c\u300cSurgery Frontier\uff5e\u7279\u96c6\uff1a\u764c\u3068\u5fae\u5c0f\u74b0\u5883\u300d\uff0c21(2)\uff0c53-57\uff0c2014 \u6a0b\u7530\u4eac\u5b50\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u3068\u65b0\u305f\u306a\u6cbb\u7642\u6226\u7565\u3078\u306e\u5c55\u671b,\u300c\u75c5\u7406\u3068\u81e8\u5e8a\uff5e\u7279\u96c6\uff1a\u304c\u3093\u3068\u9593\u8cea\u300d,32(1), 45-50, 2014 \u82f1\u8a9e\u8ad6\u6587 Kibria G., Hatakeyama H.,Akiyama K.,\u00a0Hida K. and Har…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-169","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=169"}],"version-history":[{"count":4,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/169\/revisions"}],"predecessor-version":[{"id":431,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/169\/revisions\/431"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}